WO2025094117 - SUBSTITUTED INDOLYL COMPOUNDS, COMPOSITIONS THEREOF, AND THERAPEUTIC USES THEREOF
National phase entry:
Publication Number
WO/2025/094117
Publication Date
08.05.2025
International Application No.
PCT/IB2024/060783
International Filing Date
31.10.2024
Title **
[English]
SUBSTITUTED INDOLYL COMPOUNDS, COMPOSITIONS THEREOF, AND THERAPEUTIC USES THEREOF
[French]
COMPOSÉS INDOLYLES SUBSTITUÉS, LEURS COMPOSITIONS ET LEURS UTILISATIONS THÉRAPEUTIQUES
Applicants **
GT GAIN THERAPEUTICS SA
Inventors
GARCÍA COLLAZO, Ana Maria
TRAPERO PUIG, Ana
Priority Data
23383116.3
02.11.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3298 | |
| EPO | Filing, Examination, Granting | 24202 | |
| Japan | Filing, Examination, Granting | 3019 | |
| South Korea | Filing, Examination, Granting | 3831 | |
| USA | Filing, Examination, Granting | 19540 |
Total:
53,890
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
are defined as set forth in the specification, and their use in the treatment and/or prevention of diseases and conditions associated with the alteration of the activity of β-galactosidase, specially galactosidase β-1 or GLB1, including GM1 gangliosidosis and Morquio syndrome, Type B.[French]
étant tels que définis dans la description, et leur utilisation dans le traitement et/ou la prévention de maladies et affections associées à l'altération de l'activité de la β-galactosidase, spécialement de la galactosidase β-1 ou GLB1, y compris la gangliosidose GM1 et le syndrome de Morquio, de type B.